Reckitt Benckiser Group PLC Acquisition

Reckitt Benckiser Group PLC Acquisition


RNS Number : 8879B

Reckitt Benckiser Group PLC

10 March 2014

Slough, England - March 10, 2014- Reckitt Benckiser Group PLC ("RB") (LSE: RB) today announces that it has signed a definitive agreement to acquire from McNEIL-PPC, Inc, a subsidiary of Johnson & Johnson, the global rights to the K-Y brand ("K-Y"), a leader in intimate lubricants. The transaction is subject to customary regulatory approvals and closing conditions and is expected to close in mid 2014. No employees or fixed assets are included in the purchase.

K-Y started as a prescription medical device in 1917 and switched to over-the-counter in 1980. The brand's clinical and professional heritage is unique in the category and is the underpinning to its trusted and professionally endorsed position. It has been the historical innovator in the category and was the brand that built the female intimacy enhancement segment in lubricants.

K-Y, as a global leader in intimate lubricants with very high trust score amongst women, will sit alongside the RB Powerbrand Durex to create a unique portfolio of brands in the sexual wellbeing category. Its addition will immediately transform RB's sexual well-being category in the USA and Brazil. K-Y will benefit from RB's strong innovation, brand equity investment and go-to-market capabilities.

Net sales of K-Y in 2013 were greater than $100 million. It is sold in over 50 countries around the world, with the US, Canada and Brazil accounting for the majority of 2013 sales.

For queries contact:

For further information, please contact:

Reckitt Benckiser
  Richard Joyce
  Director, Investor Relations
  Andraea Dawson-Shepherd                            +44 (0)1753 217800
  SVP, Global Corporate Communication & Affairs       +44 (0)1753 446447
Brunswick (Financial PR)                              +44 (0)20 7404
  David Litterick                                           5959

This information is provided by RNS

The company news service from the London Stock Exchange



Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.